🚀 VC round data is live in beta, check it out!
Yixintang Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for Yixintang Pharmaceutical and similar public comparables like Anhui Huaren Health, Aldawaa Medical Services, Medplus Health Services, Selçuk Ecza and more.
Yixintang Pharmaceutical Overview
About Yixintang Pharmaceutical
Yixintang Pharmaceutical Group Co Ltd is a China-based company engages in the operation of pharmaceutical retail chains and wholesale businesses. Its products include traditional Chinese medicine, Western medicine, and medical equipment.
Founded
2000
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$1B
Yixintang Pharmaceutical Financials
Yixintang Pharmaceutical reported last 12-month revenue of $3B and EBITDA of $111M.
In the same LTM period, Yixintang Pharmaceutical generated $991M in gross profit, $111M in EBITDA, and $55M in net income.
Revenue (LTM)
Yixintang Pharmaceutical P&L
In the most recent fiscal year, Yixintang Pharmaceutical reported revenue of $3B and EBITDA of $234M.
Yixintang Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $991M | XXX | $831M | XXX | XXX | XXX |
| Gross Margin | 39% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $111M | XXX | $234M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $55M | XXX | $17M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 1% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Yixintang Pharmaceutical Stock Performance
Yixintang Pharmaceutical has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Yixintang Pharmaceutical's stock price is $1.97.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 1.0% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYixintang Pharmaceutical Valuation Multiples
Yixintang Pharmaceutical trades at 0.4x EV/Revenue multiple, and 9.9x EV/EBITDA.
EV / Revenue (LTM)
Yixintang Pharmaceutical Financial Valuation Multiples
As of March 19, 2026, Yixintang Pharmaceutical has market cap of $1B and EV of $1B.
Equity research analysts estimate Yixintang Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yixintang Pharmaceutical has a P/E ratio of 21.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBIT | 10.9x | XXX | 13.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.1x | XXX | 1.3x | XXX | XXX | XXX |
| P/E | 21.1x | XXX | 69.5x | XXX | XXX | XXX |
| EV/FCF | 7.5x | XXX | 5.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yixintang Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Yixintang Pharmaceutical Margins & Growth Rates
Yixintang Pharmaceutical's revenue in the last 12 month grew by 8%.
Yixintang Pharmaceutical's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yixintang Pharmaceutical's rule of X is 24% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Yixintang Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | (56%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 24% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 25% | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Yixintang Pharmaceutical Public Comps
See public comps and valuation multiples for other Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Anhui Huaren Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Aldawaa Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Medplus Health Services | XXX | XXX | XXX | XXX | XXX | XXX |
| Selçuk Ecza | XXX | XXX | XXX | XXX | XXX | XXX |
| Create SD Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yixintang Pharmaceutical M&A Activity
Yixintang Pharmaceutical acquired XXX companies to date.
Last acquisition by Yixintang Pharmaceutical was on XXXXXXXX, XXXXX. Yixintang Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Yixintang Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYixintang Pharmaceutical Investment Activity
Yixintang Pharmaceutical invested in XXX companies to date.
Yixintang Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. Yixintang Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Yixintang Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yixintang Pharmaceutical
| When was Yixintang Pharmaceutical founded? | Yixintang Pharmaceutical was founded in 2000. |
| Where is Yixintang Pharmaceutical headquartered? | Yixintang Pharmaceutical is headquartered in China. |
| Is Yixintang Pharmaceutical publicly listed? | Yes, Yixintang Pharmaceutical is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yixintang Pharmaceutical? | Yixintang Pharmaceutical trades under 002727 ticker. |
| When did Yixintang Pharmaceutical go public? | Yixintang Pharmaceutical went public in 2014. |
| Who are competitors of Yixintang Pharmaceutical? | Yixintang Pharmaceutical main competitors are Anhui Huaren Health, Aldawaa Medical Services, Medplus Health Services, Selçuk Ecza. |
| What is the current market cap of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's current market cap is $1B. |
| What is the current revenue of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months revenue is $3B. |
| What is the current revenue growth of Yixintang Pharmaceutical? | Yixintang Pharmaceutical revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Yixintang Pharmaceutical? | Current revenue multiple of Yixintang Pharmaceutical is 0.4x. |
| Is Yixintang Pharmaceutical profitable? | Yes, Yixintang Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months EBITDA is $111M. |
| What is Yixintang Pharmaceutical's EBITDA margin? | Yixintang Pharmaceutical's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Yixintang Pharmaceutical? | Current EBITDA multiple of Yixintang Pharmaceutical is 9.9x. |
| What is the current FCF of Yixintang Pharmaceutical? | Yixintang Pharmaceutical's last 12 months FCF is $146M. |
| What is Yixintang Pharmaceutical's FCF margin? | Yixintang Pharmaceutical's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Yixintang Pharmaceutical? | Current FCF multiple of Yixintang Pharmaceutical is 7.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.